Document Detail


Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer.
MedLine Citation:
PMID:  20978159     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to determine the anticancer efficacy of 1,1-bis (3'-indolyl)-1-(p-biphenyl) methane (DIM-C-pPhC₆H₅) by inhalation delivery alone and in combination with i.v. docetaxel in a murine model for lung cancer. An aqueous DIM-C-pPhC₆H₅ formulation was characterized for its aerodynamic properties. Tumor-bearing athymic nude mice were exposed to nebulized DIM-C-pPhC₆H₅, docetaxel, or combination (DIM-C-pPhC₆H₅ plus docetaxel) using a nose-only exposure technique. The aerodynamic properties included mass median aerodynamic diameter of 1.8 ± 0.3 μm and geometric SD of 2.31 ± 0.02. Lung weight reduction in mice treated with the drug combination was 64% compared with 40% and 47% in mice treated with DIM-C-pPhC₆H₅ aerosol and docetaxel alone, respectively. Combination treatment decreased expression of Akt, cyclin D1, survivin, Mcl-1, NF-κB, IκBα, phospho-IκBα, and vascular endothelial growth factor (VEGF) and increased expression of c-Jun NH₂-terminal kinase 2 and Bad compared with tumors collected from single-agent treatment and control groups. DNA fragmentation was also enhanced in mice treated with the drug combination compared with docetaxel or DIM-C-pPhC₆H₅ alone. Combination treatment decreased expressions of VEGF and CD31 compared with single-agent treated and control groups. These results suggest that DIM-C-pPhC₆H₅ aerosol enhanced the anticancer activity of docetaxel in a lung cancer model by activating multiple signaling pathways. The study provides evidence that DIM-C-pPhC₆H₅ can be used alone or in combination with other drugs for the treatment of lung cancer using the inhalation delivery approach.
Authors:
Nkechi Ichite; Mahavir Chougule; Apurva R Patel; Tanise Jackson; Stephen Safe; Mandip Singh
Related Documents :
10840069 - The use of thymidylate synthase inhibitors in the treatment of advanced colorectal canc...
16732719 - Epothilones in the treatment of cancer.
7865429 - Combination chemotherapy with taxol (paclitaxel) in metastatic breast cancer.
9292709 - Treatment of advanced colorectal cancer with doxorubicin combined with two potential mu...
779949 - Phase iii comparison of the treatment of advanced gastrointestinal cancer with bolus we...
15289729 - Effect of capecitabine on mean corpuscular volume in patients with metastatic breast ca...
21479069 - Quality oncology practice initiative certification program: overview, measure scoring m...
22357149 - Patient-related barriers to cancer pain management in jordan.
3326659 - Psychiatric aspects of cancer in the aged.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-10-26
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  9     ISSN:  1538-8514     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-11     Completed Date:  2011-02-28     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3003-14     Citation Subset:  IM    
Copyright Information:
©2010 AACR.
Affiliation:
College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Animals
Antineoplastic Agents / administration & dosage,  adverse effects
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cell Line, Tumor
Drug Delivery Systems
Female
Humans
Indoles / administration & dosage*,  adverse effects,  chemistry
Lung Neoplasms / drug therapy*,  pathology
Mice
Mice, Nude
Models, Biological
Nasal Sprays
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
5S06GM008111-36/GM/NIGMS NIH HHS; CA108718/CA/NCI NIH HHS; CA112337/CA/NCI NIH HHS; G12 RR003020/RR/NCRR NIH HHS; G12RR03020-11/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/1,1-bis(3'-indolyl)-1-(4-biphenyl)methane; 0/Antineoplastic Agents; 0/Indoles; 0/Nasal Sprays; 0/diindolylmethane
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel human dynactin-associated protein, dynAP, promotes activation of Akt, and ergosterol-related...
Next Document:  Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen spe...